1093064-85-7

Upstream product

• 57988-58-6 4-(4-bromophenyl)-4-hydroxy-piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 163209-96-9 tert-butyl 4-(4-bromophenyl)-4-hydroxypiperidine-1-carboxylate 

Downstream Products

• 1374342-23-0 C₃₄H₃₃ClF₄N₄O₄ 
• 1374342-24-1 C₃₄H₃₂ClF₃N₄O₄ 
• 1374342-20-7 tert-butyl 4-fluoro-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine-1-carboxylate 

Relevant academic research and scientific papers

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

DIAZACARBAZOLES AND METHODS OF USE

The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chkl) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.